QuantumPharm, Inc. (2228) Stock Statistics & Valuation Metrics

QuantumPharm, Inc. has a market cap or net worth of HK$41.34B. The enterprise value is HK$33.91B.

QuantumPharm, Inc. has 4,303,371,600 shares outstanding. The number of shares has decreased by -2.65% in one year.

QuantumPharm, Inc.’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is -4.98%.

The current PE Ratio of QuantumPharm, Inc. is 266.6. QuantumPharm, Inc.’s PEG ratio is -2.56.

In the last 12 months, QuantumPharm, Inc. had revenue of 781.85M and earned 120.54M in profits. Earnings per share was 0.03.

In the last 12 months, operating cash flow was -148.53M and capital expenditures -62.03M, giving a free cash flow of -210.56M billion.

QuantumPharm, Inc. pays an annual dividend of HK$0.007, resulting in a dividend yield of ―

QuantumPharm, Inc. upcoming earnings date is Sep 2, 2026, Before Open (Confirmed).

QuantumPharm, Inc. as a current ratio of 14.77, with Debt / Equity ratio of 4.72%

In the past 12 months, QuantumPharm, Inc. has paid 758.84K in taxes.

QuantumPharm, Inc. EV to EBITDA ratio is -78.12, with an EV/FCF ratio of -149.98.

QuantumPharm, Inc. has HK$7.07B in cash and marketable securities with HK$443.46M in debt, giving a net cash position of HK$6.63B billion.

Gross margin is 69.83%, with operating margin of -63.50%, and net profit margin of 15.42%.

The average price target for QuantumPharm, Inc. is HK$15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy